Literature DB >> 19920198

Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

Lonneke A M Gravendeel1, Mathilde C M Kouwenhoven, Olivier Gevaert, Johan J de Rooi, Andrew P Stubbs, J Elza Duijm, Anneleen Daemen, Fonnet E Bleeker, Linda B C Bralten, Nanne K Kloosterhof, Bart De Moor, Paul H C Eilers, Peter J van der Spek, Johan M Kros, Peter A E Sillevis Smitt, Martin J van den Bent, Pim J French.   

Abstract

Gliomas are the most common primary brain tumors with heterogeneous morphology and variable prognosis. Treatment decisions in patients rely mainly on histologic classification and clinical parameters. However, differences between histologic subclasses and grades are subtle, and classifying gliomas is subject to a large interobserver variability. To improve current classification standards, we have performed gene expression profiling on a large cohort of glioma samples of all histologic subtypes and grades. We identified seven distinct molecular subgroups that correlate with survival. These include two favorable prognostic subgroups (median survival, >4.7 years), two with intermediate prognosis (median survival, 1-4 years), two with poor prognosis (median survival, <1 year), and one control group. The intrinsic molecular subtypes of glioma are different from histologic subgroups and correlate better to patient survival. The prognostic value of molecular subgroups was validated on five independent sample cohorts (The Cancer Genome Atlas, Repository for Molecular Brain Neoplasia Data, GSE12907, GSE4271, and Li and colleagues). The power of intrinsic subtyping is shown by its ability to identify a subset of prognostically favorable tumors within an external data set that contains only histologically confirmed glioblastomas (GBM). Specific genetic changes (epidermal growth factor receptor amplification, IDH1 mutation, and 1p/19q loss of heterozygosity) segregate in distinct molecular subgroups. We identified a subgroup with molecular features associated with secondary GBM, suggesting that different genetic changes drive gene expression profiles. Finally, we assessed response to treatment in molecular subgroups. Our data provide compelling evidence that expression profiling is a more accurate and objective method to classify gliomas than histologic classification. Molecular classification therefore may aid diagnosis and can guide clinical decision making.

Entities:  

Mesh:

Year:  2009        PMID: 19920198     DOI: 10.1158/0008-5472.CAN-09-2307

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  295 in total

1.  Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics.

Authors:  Mahfoud Assem; Zita Sibenaller; Supreet Agarwal; Maha S Al-Keilani; Mohammad A Y Alqudah; Timothy C Ryken
Journal:  OMICS       Date:  2012-03

2.  Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

Authors:  Fabio M Iwamoto; Andreas F Hottinger; Sasan Karimi; Elyn Riedel; Jocelynn Dantis; Maryam Jahdi; Katherine S Panageas; Andrew B Lassman; Lauren E Abrey; Martin Fleisher; Lisa M DeAngelis; Eric C Holland; Adília Hormigo
Journal:  Neuro Oncol       Date:  2011-08-10       Impact factor: 12.300

3.  Response to "From histology to neurocognition: the influence of tumor grade in glioma of the left temporal lobe on neurocognitive function".

Authors:  Kyle R Noll; Jeffrey S Wefel
Journal:  Neuro Oncol       Date:  2015-10       Impact factor: 12.300

4.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.

Authors:  Krishna P L Bhat; Veerakumar Balasubramaniyan; Brian Vaillant; Ravesanker Ezhilarasan; Howard Colman; Erik P Sulman; Kenneth Aldape; Karlijn Hummelink; Faith Hollingsworth; Khalida Wani; Lindsey Heathcock; Johanna D James; Lindsey D Goodman; Siobhan Conroy; Lihong Long; Nina Lelic; Suzhen Wang; Joy Gumin; Divya Raj; Yoshinori Kodama; Aditya Raghunathan; Adriana Olar; Kaushal Joshi; Christopher E Pelloski; Amy Heimberger; Se Hoon Kim; Daniel P Cahill; Ganesh Rao; Wilfred F A Den Dunnen; Hendrikus W G M Boddeke; Heidi S Phillips; Ichiro Nakano; Frederick F Lang
Journal:  Cancer Cell       Date:  2013-08-29       Impact factor: 31.743

5.  Nicotinamide metabolism regulates glioblastoma stem cell maintenance.

Authors:  Jinkyu Jung; Leo Jy Kim; Xiuxing Wang; Qiulian Wu; Tanwarat Sanvoranart; Christopher G Hubert; Briana C Prager; Lisa C Wallace; Xun Jin; Stephen C Mack; Jeremy N Rich
Journal:  JCI Insight       Date:  2017-05-18

6.  Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.

Authors:  Jeffrey S Wefel; Kyle R Noll; Ganesh Rao; Daniel P Cahill
Journal:  Neuro Oncol       Date:  2016-08-30       Impact factor: 12.300

7.  Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.

Authors:  Wei Yan; Wei Zhang; Gan You; Junxia Zhang; Lei Han; Zhaoshi Bao; Yongzhi Wang; Yanwei Liu; Chuanlu Jiang; Chunsheng Kang; Yongping You; Tao Jiang
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

8.  Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells.

Authors:  Yukti Choudhury; Felix Chang Tay; Dang Hoang Lam; Edwin Sandanaraj; Carol Tang; Beng-Ti Ang; Shu Wang
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

9.  Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules.

Authors:  Rutger K Balvers; Anne Kleijn; Jenneke J Kloezeman; Pim J French; Andreas Kremer; Martin J van den Bent; Clemens M F Dirven; Sieger Leenstra; Martine L M Lamfers
Journal:  Neuro Oncol       Date:  2013-09-17       Impact factor: 12.300

10.  A glioma classification scheme based on coexpression modules of EGFR and PDGFRA.

Authors:  Yingyu Sun; Wei Zhang; Dongfeng Chen; Yuhong Lv; Junxiong Zheng; Henrik Lilljebjörn; Liang Ran; Zhaoshi Bao; Charlotte Soneson; Hans Olov Sjögren; Leif G Salford; Jianguang Ji; Pim J French; Thoas Fioretos; Tao Jiang; Xiaolong Fan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.